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Type II Toxoplasma gondii KU80 knockouts (ku80) deficient in nonhomologous end joining were developed
to delete the dominant pathway mediating random integration of targeting episomes. Gene targeting frequency
in the type II ku80 hxgprt strain measured at the orotate (OPRT) and the uracil (UPRT) phosphoribosyl-
transferase loci was highly efficient. To assess the potential of the type II ku80 hxgprt strain to examine gene
function affecting cyst biology and latent stages of infection, we targeted the deletion of four parasite antigen
genes (GRA4, GRA6, ROP7, and tgd057) that encode characterized CD8 T cell epitopes that elicit correspond-
ing antigen-specific CD8 T cell populations associated with control of infection. Cyst development in these
type II mutant strains was not found to be strictly dependent on antigen-specific CD8 T cell host responses.
In contrast, a significant biological role was revealed for the dense granule proteins GRA4 and GRA6 in cyst
development since brain tissue cyst burdens were drastically reduced specifically in mutant strains with GRA4
and/or GRA6 deleted. Complementation of the gra4 and gra6 mutant strains using a functional allele of the
deleted GRA coding region placed under the control of the endogenous UPRT locus was found to significantly
restore brain cyst burdens. These results reveal that GRA proteins play a functional role in establishing cyst
burdens and latent infection. Collectively, our results suggest that a type II ku80 hxgprt genetic background
enables a higher-throughput functional analysis of the parasite genome to reveal fundamental aspects of
parasite biology controlling virulence, pathogenesis, and transmission.
Toxoplasma gondii is an extremely widespread obligate in-
tracellular protozoan pathogen of virtually all warm-blooded
animals (19). Infection is initiated following oral ingestion of
transmissible parasite stages included within cysts contained in
infected meat or within oocysts released in the environment by
cat feces. Primary T. gondii infection rarely causes significant
disease in the nonimmunocompromised individual, unless in-
fection is transmitted in utero (50). Latent T. gondii infection is
characterized by the presence of tissue cysts containing non-
replicating bradyzoites. The cysts persist primarily in muscles,
the eyes, and the brain (19). For unknown reasons, latent tissue
cysts occasionally rupture, and this cyst reactivation can lead to
recrudescent disease. By example, infection in utero is associ-
ated with the highest risk of later development of ocular tox-
oplasmosis (66), a significant recurrent retinal infection (36).
Immunosuppression markedly increases the likelihood of cyst
rupture, conversion of latent bradyzoites to rapidly dividing
tachyzoites, and the development of reactivated disease (51).
Immune control of latent infection fails in AIDS and other
severe immunodeficiencies, resulting in a recrudescent acute
infection and causing a potentially lethal toxoplasmic enceph-
alitis (12).
T. gondii has rapidly developed as an outstanding model
organism for obligate intracellular eukaryotic pathogens (40,
53). Within the single genus and species T. gondii, three major
strain types were defined by their virulence phenotype in mice
(58). Currently, type I strains of T. gondii are excellent in vitro
models, but this acutely virulent strain type does not readily
develop tissue cysts or latent infection in laboratory mice. In
contrast, type II strains of T. gondii easily establish latent in-
fections in mice that are characterized by the presence of tissue
cysts, the key obligate developmental and latent stage required
for the remarkably high transmission potential of this parasite
(52). Oral transmission appears to have driven the recent
clonal expansion of strains that predominate in North America
and Europe (62). Type II strains represent the most prevalent
strain type chronically infecting North American and Euro-
pean populations (33). After oral ingestion of a tissue cyst in a
naive host, the encysted bradyzoite reactivates and converts
back to the rapidly dividing tachyzoite form that causes dis-
seminated acute infection, followed later by cyst development
and the establishment of a latent infection in the host (19).
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While induction of tachyzoite to bradyzoite conversion in vitro
can be triggered by various stress responses (temperature, high
pH, chemical stress, nutrient stress, and cytokines) (67), little is
currently known regarding fundamental parasite biology un-
derlying acute and latent phases of infection in vivo.
Host-parasite interaction in acute and latent phases of type
II T. gondii infection is dynamic. During acute infection T.
gondii selectively invades host cell types primarily of the den-
dritic, macrophage, and neutrophil lineages (4, 11, 31). By
invading host cell types that are critical to mounting effective
innate responses to infection, the parasite actively seeks to
manipulate the host through several mechanisms (14). Despite
or because of this strategy, the host rapidly mounts highly
effective CD8 T cell responses associated with strong inter-
feron gamma (IFN-) responses (26, 58). These innate and
adaptive immune responses are required to achieve control of
acute infection and may also trigger tachyzoite to bradyzoite
conversion and development of the latent transmissible tissue
cyst (29, 63, 67).
Several landmark studies have recently identified four par-
asite antigen genes (GRA4, GRA6, ROP7, and tgd057) that
possess CD8 T cell epitopes that elicit corresponding antigen-
specific CD8 T cells associated with the immune control of T.
gondii infection (5, 27, 42, 68). The ROP7 protein of unknown
function belongs to a family of rhoptry proteins localized to the
parasite rhoptry organelles. These Apicomplexa-specific secre-
tory organelles discharge their contents into the host cytosol
during invasion of the host cell (7). The parasite dense granule
(GRA) proteins GRA4 and GRA6 are members of the Toxo-
plasma prominent dense granule protein family (46, 49). Dense
granule proteins are highly expressed proteins. The dense
granule secretory organelles discharge their contents into the
parasitophorous vacuole (PV) space following host cell inva-
sion and the initial formation of the parasitophorous vacuole
membrane (PVM) (9). A newly proposed member of the dense
granule protein family called GRA15 localized to the dense
granules, the PV space, the space outside of the PVM, and was
also associated with evacuoles, suggesting that GRA15 is also
a rhoptry-like protein in potentially being secreted during in-
vasion of the host cell (54). GRA15 plays a significant role in
host cell NF-B nuclear translocation and NF-B-mediated
transcription and regulates the induction of IL-12 secretion in
infected mouse macrophages (54). Various potential biological
roles for GRA proteins have been previously proposed and
significant studies have been performed on GRA protein se-
cretion, traffic, and interaction biology (10, 49). At the
tachyzoite stage, most of the GRA proteins associate with the
PV membranes, meaning either the PVM and its digitations or
the intravacuolar network of membranous tubules (49). At the
bradyzoite stage, most of the GRA proteins were localized at
the cyst wall or in the cyst matrix (64).
Type I mutants deleted in GRA2 or GRA6 showed a phe-
notype of reduced acute virulence during infection in mice (48;
C. Mercier, unpublished data). However, to date, the only
GRA proteins successfully disrupted in the type II background
are GRA3 (13) and GRA15 (54). Disruption of type II GRA3
resulted in a phenotype of reduced acute virulence (13). Dis-
ruption of type II GRA15 increased parasite burdens in in-
fected mice without influencing virulence (54). These previous
studies did not address a functional role for GRA proteins in
cyst development during infection. While GRA proteins ap-
pear to be central to the host-parasite relationship, it is cur-
rently unknown whether GRA proteins are required to estab-
lish latent infection.
Tachyzoite-to-bradyzoite conversion, cyst development, and
latent infection are critical to parasite survival and transmis-
sion. Nine distinct targeted gene deletions (1, 6, 13, 32, 38, 54,
55, 57, 65, 69) have been successfully developed in type II
strains since genetic transformation of T. gondii was reported
nearly 20 years ago (18, 39, 61). In contrast, recently reported
type I KU80 knockout strains that exhibit highly efficient gene
replacement frequencies has significantly accelerated the de-
velopment of targeted gene deletions (2, 3, 15, 20, 23, 26, 34,
37, 44). Increased efficiency of double-crossover homologous
recombination at targeted loci in KU80 knockouts is due to the
functional loss of the nonhomologous end-joining DNA repair
pathway that mediates a major mechanism underlying frequent
random insertion of linear episomes in T. gondii (26). We
report here the development of KU80 knockouts (ku80) in
type II T. gondii. Eight genetic loci were targeted for the
development of mutant strains with targeted single-gene dele-
tions or multiple-gene deletions to functionally examine can-
didate genes required for cyst development and latent infec-
tion. In particular, we examined the hypothesis that a host
response to parasite antigen genes that elicit antigen-specific
CD8 T cell responses during host infection may be essential
to cyst development. Our results support a critical role for
dense granule proteins GRA4 and GRA6 in fundamental bi-
ology at the host-parasite interface that is essential for cyst
development and transmission of T. gondii.
MATERIALS AND METHODS
Primers. All oligonucleotide primers used in the development of plasmids for
targeting gene deletions are listed in Table S1 in the supplemental material. All
oligonucleotide primers used in validation of mutants with gene deletions are
listed in Table S2 in the supplemental material.
Plasmid constructs. All plasmids were developed using the yeast shuttle vector
pRS416 and yeast recombination cloning which fused three distinct genetic
elements (an 1-kb 5 target flank, an 2-kb hypoxanthine-xanthine-guanine
phosphoribosyltransferase [HXGPRT] selectable marker cassette, and an 1-kb
3 target flank, all 5 to 3 and in this order) with pRS416 using 31- to 33-bp
homologous crossovers at recombination junctions (23). DNA elements for yeast
recombination were amplified from type II Prugniaud (Pru) genomic DNA or
type I RH genomic DNA as indicated. Targeting plasmids constructed in pRS416
were verified by using restriction enzyme digests, and target DNA flanks were
sequenced to verify DNA sequence homology.
Plasmid pTPR1 was constructed to delete nucleotides 2741952 to 2737843 in
the Pru KU80 locus, defined as TGME49_112510 on chrXI of the ToxoDB
database version 6.0 (www.toxodb.org). This deletion strategy deletes 1,228 bp of
the KU80 5 upstream putative gene regulatory region and the first three exons
of the predicted four protein coding exons of the KU80 gene. The HXGPRT
minigene cassette was fused between a 2,997-bp 5 genomic targeting flank and
a 3,304-bp 3 genomic targeting flank amplified from Pru genomic DNA.
Plasmid pTPFC1 was constructed by NotI and PmeI digestion of pTPR1 at
the 3 end of the 3 targeting flank, followed by ligation with the cytosine
deaminase (CD) selectable marker contained on a NotI/PmeI restriction frag-
ment isolated from plasmid pMCD4.4 (26).
Plasmid pTPRC2 was constructed by digesting pTPR1 with KspI, followed
by self-ligation to delete the HXGPRT minicassette fragment from pTPR1.
Plasmid pUPRP was constructed to delete nucleotides 2709350 to 2713372 of
the uracil phosphoribosyltransferase (UPRT) chromosomal locus on chrXI an-
notated as TGME49_112480. The HXGPRT minigene cassette was fused be-
tween a 1,131-bp 5 UPRT genomic targeting flank and a 1,119-bp 3 UPRT
genomic targeting flank amplified from Pru genomic DNA.
Plasmid pUPP was constructed to delete nucleotides 1491873 to 1488688 of
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the uridine phosphorylase (UP) chromosomal locus (23) on chrXI annotated as
TGME49_110640. The HXGPRT minigene cassette was fused between a
1,141-bp 5 UP genomic targeting flank and a 955-bp 3 UP genomic targeting
flank amplified from Pru genomic DNA.
Plasmid pOPT was constructed to delete nucleotides 2733578 to 2735556 of
the orotate phosphoribosyltransferase (OPRT) locus defined as TGGT1_010360
on chrVIIb. The HXGPRT minigene cassette was fused between a 1,050-bp 5
OPRT genomic targeting flank and a 1,118-bp 3 OPRT genomic targeting flank
amplified from RH genomic DNA.
Plasmid pOPP was constructed to delete nucleotides 2719166 to 2721148 of
the OPRT locus defined as TGME49_059660 on chrVIIb. The HXGPRT mini-
gene cassette was fused between a 1,050-bp 5OPRT genomic targeting flank and
a 1,118-bp 3 OPRT genomic targeting flank amplified from Pru genomic DNA.
Plasmid pOPPC was constructed by digesting pOPP with SacII, followed by
self-ligation to delete the HXGPRT minicassette.
Plasmid pGRA4P was constructed to delete nucleotides 1581347 to 1570147
of the GRA4 locus on chrXI annotated as TGME49_110780. The HXGPRT
minigene cassette was fused between a 1,124-bp 5 GRA4 genomic targeting
flank and a 989-bp 3GRA4 genomic targeting flank amplified from Pru genomic
DNA.
Plasmid pGRA4PC was constructed by digesting pGRA4 with SpeI, fol-
lowed by self-ligation to delete the HXGPRT minicassette.
Plasmid pGRA6P was constructed to delete nucleotides 7216123 to 7215219
of the GRA6 locus on chrX annotated as TGME49_075440. The HXGPRT
minigene cassette was fused between a 1,048-bp 5 GRA6 genomic targeting
flank and a 955-bp 3 GRA6 genomic targeting flank amplified from Pru
genomic DNA.
Plasmid pGRA6PC was constructed by digesting pGRA6 with SpeI, fol-
lowed by self-ligation to delete the HXGPRT minicassette.
Plasmid pROP4/7P was constructed to delete nucleotides 1414364 to
1404628 of the ROP4/7 locus on chr1a annotated as TGME49_095110. This gene
locus is incomplete in the genome database. Analysis of the Toxodb database
identified common flanking and unique DNA surrounding the ROP4/7 locus and
suggested the gene structure for the ROP4/7 locus consists of a 5 ROP4 gene,
followed by a complete ROP7A allele and ROP7B allele (with identical coding
DNA but minor polymorphisms in their UTRs) and a 3 truncated and incom-
plete ROP7C allele (L. M. Rommereim and D. J. Bzik, unpublished data).
Consequently, we targeted the deletion of the entire locus (14,297 bp) and all
ROP4 and ROP7 alleles by using target DNA flanks derived from unique DNA
sequences that reside just 5 or just 3 of the ROP4/7 locus. The HXGPRT
minigene cassette was fused between a 1,179-bp 5 ROP4/7 genomic targeting
flank and a 989-bp 3 ROP4/7 genomic targeting flank amplified from Pru
genomic DNA.
Plasmid pTGD057P was constructed to delete nucleotides 6486828 to
6487525 of the tgd057 locus on chrXI annotated as TGME49_015980. The
HXGPRT minigene cassette was fused between an 800-bp 5 tgd057 genomic
targeting flank and a 1,259-bp 3 tgd057 genomic targeting flank amplified from
Pru genomic DNA.
Plasmid pGRA4X was constructed to insert the coding region of GRA4 into
the UPRT locus under the control of the UPRT 5 transcribed, untranslated
region (5UTR). Targeted insertion of the pGRA4X cassette deleted nucleotides
2709350 to 2713372 of the coding region of the UPRT chromosomal locus on
chrXI annotated as TGME49_112480. The GRA4 coding region (plus 12 bp 5 of
the ATG) and 635 bp of the GRA4 3UTR (nucleotides 1579415 to 1581100 on
ChrXI) was amplified from Pru genomic DNA and inserted between the 5
UPRT target flank and the HXGPRT marker of plasmid pUPRP.
Plasmid pGRA6X was constructed to insert the coding region of GRA6 into
the UPRT locus under the control of the UPRT 5UTR. Targeted insertion of the
pGRA6X cassette deleted nucleotides 2709350 to 2713372 of the coding region
of the UPRT chromosomal locus on chrXI annotated as TGME49_112480. The
GRA6 coding region (plus 15 bp 5 of the ATG) and 542 bp of the GRA6 3UTR
(nucleotides 7214586 to 7215818 on ChrX) was amplified from Pru genomic
DNA and inserted between the 5 UPRT target flank and the HXGPRT marker
of plasmid pUPRP.
Culture conditions and strains. All parasite strains were continuously main-
tained in vitro by serial passage in Eagle modified essential medium supple-
mented with 1% fetal bovine serum in diploid human foreskin fibroblasts (HFF)
at 36°C (26). Pyrimidine auxotrophs were supplemented with uracil (250 M).
The parental Pru strain (hxgprt) was previously made transgenic for green
fluorescent protein (GFP) under the control of the LDH2 bradyzoite stage-
specific promoter and was designated BSG-4 (60). The T. gondii strains used and
developed in the present study are shown in Table 1. We previously reported the
RHku80hxgprt strain (26).
Transformation, selection, and gene deletion verification strategy. Electropo-
rations were performed using a model BTX600 electroporator and previously
described methods (26). All transfected plasmids were linearized 5 of the 5
target DNA flank prior to transfection using unique restriction enzyme sites
designed into the targeting plasmids. Forward selections to integrate the pmini-
HXGPRT selectable marker were performed in mycophenolic acid (MPA; 25
g/ml) and xanthine (50 g/ml) (16, 26). Negative selections to excise HXGPRT
were performed in 6-thioxanthine (6TX) (200 g/ml) (23, 26). Negative selec-
tions using the cytosine deaminase (CD) selectable marker were performed in
TABLE 1. T. gondii strains used and developed in this studya
Strain Parent strain(source or reference) Genotype
Pruku80::HXGPRT Pruhxgprt (BSG-4) (60) ku80
Pruku80hxgprt Pruku80::HXGPRT ku80 hxgprt
Pruku80uprt::HXGPRT Pruku80hxgprt ku80 uprt::HXGPRT
RHku80oprt::HXGPRT RHku80hxgprt (26) ku80 oprt::HXGPRT
Pruku80oprt::HXGPRT Pruku80hxgprt ku80 oprt::HXGPRT
Pruku80oprthxgprt Pruku80oprt::HXGPRT ku80 oprt hxgprt
Pruku80up::HXGPRT Pruku80hxgprt ku80 up::HXGPRT
Pruku80gra4::HXGPRT Pruku80hxgprt ku80 gra4::HXGPRT
Pruku80gra4hxgprt Pruku80gra4::HXGPRT ku80 gra4 hxgprt
Pruku80gra6::HXGPRT Pruku80hxgprt ku80 gra6::HXGPRT
Pruku80gra6hxgprt Pruku80gra6::HXGPRT ku80 gra6 hxgprt
Pruku80tgd057::HXGPRT Pruku80hxgprt ku80 tgd057::HXGPRT
Pruku80rop4/7::HXGPRT Pruku80hxgprt ku80 rop4/7::HXGPRT
Pruku80gra4tgd057::HXGPRT Pruku80gra4hxgprt ku80 gra4 tgd057::HXGPRT
Pruku80gra6tgd057::HXGPRT Pruku80gra6hxgprt ku80 gra6 tgd057::HXGPRT
Pruku80gra6gra4::HXGPRT Pruku80gra6hxgprt ku80 gra6 gra4::HXGPRT
Pruku80gra6gra4hxgprt Pruku80gra6gra4::HXGPRT ku80 gra6 gra4 hxgprt
Pruku80gra4uprt::gra4coding region  3UTRHXGPRT Pruku80gra4hxgprt ku80 gra4 uprt::gra4coding region  3UTR
HXGPRT
Pruku80gra6uprt::gra6coding region  3UTRHXGPRT Pruku80gra6hxgprt ku80 gra6 uprt::gra6coding region  3UTR
HXGPRT
a All strains used and developed in this study are transgenic for LDH2-GFP and the chloramphenicol drug resistance marker (CAT) randomly integrated into the
parental Pru strain at undefined genetic loci (60).
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5-fluorocytosine (5FC; 50 M) (22, 26). Negative selections to delete UPRT
were performed in 5 M 5-fluorodeoxyuridine (FUDR) (17). After transfection,
parasites were allowed to replicate for 24 h without selection to allow replication
and ramp up homologous recombination, and then selections were launched and
continuously maintained through verification steps of cloned isolates. The strat-
egy for verification of mutant strains was previously described (23, 26).
Genomic DNA isolation and PCR. Genomic DNA purifications used a DNA
blood minikit (Qiagen) and were performed with a Qiacube automated robotic
work station (Qiagen). PCR products were amplified using a 1:1 mixture of Taq
DNA polymerase and an Expand long-template PCR (Roche).
Determination of gene replacement frequencies and statistical analysis. PFU
assays were used to determine gene replacement frequencies. Three replicate
PFU flasks were prepared for each titration point and selection condition. A
Student t test analysis was used to calculate the standard error of the mean
(SEM). PFU assays were performed at various times after transfection to deter-
mine the gene replacement frequency at the UPRT locus based on the fraction of
parasites that had dual resistance to MPA and FUDR compared to the fraction
of parasites that were resistant only to MPA (26). PFU assays were performed at
various times after transfection to determine the gene replacement frequency at
the OPRT locus based on the fraction of parasites that exhibited resistance to
MPA and grew with uracil supplementation compared to the fraction of parasites
that were resistant to MPA without uracil supplementation (25).
Determination of the replication rate of mutant strains in vitro. The intracel-
lular growth rate of various type II strains was measured in HFFs in a 45-h
growth assay using previously described methods (24). Briefly, freshly lysed
tachyzoites were Nuclepore filtered to isolate individual tachyzoites that were
used to infect HFF monolayers at a multiplicity of infection of 0.1. After 1 h of
invasion, the culture was vigorously washed four times in phosphate-buffered
saline (PBS) to remove extracellular tachyzoites (verified by microscopy). Cul-
tures were then returned to growth medium, and the number of parasites per
vacuole was scored from at least 50 vacuoles per sample at 45 h postinfection.
Cultures were prepared in duplicate, and the growth assay was repeated twice.
The data samples were subjected to a Student t test and are represented as the
means (parasites per vacuole)  the SEM. Differences in parasites per vacuole
were compared for parental and mutant strains matched for the presence or
absence of HXGPRT. A P value of 	0.05 was considered significant.
Mice. Female 7- to 9-week-old C57BL/6 (H-2Kb), CBA (H-2Kk), and BALB/c
(H-2Ld) mice were purchased from Jackson laboratories (Bar Harbor, ME) and
maintained at the Dartmouth-Hitchcock Medical Center mouse facility. All mice
were cared for and handled according to Animal Care and Use Program of
Dartmouth College using National Institutes of Health (NIH)-approved institu-
tional animal care and use committee guidelines. Groups of mice (as indicated)
were infected by oral gavage with 10 cysts or were infected by intraperitoneal
injection with 0.2 ml (200 tachyzoites) of various Pru genotypes in PBS. Each
tachyzoite preparation was subjected to a PFU assay to determine viability. All
mice infected with tachyzoites received 130 to 252 PFU. Infected mice were then
monitored daily for wellness.
Cyst isolation, visualization, enumeration, and size determination. Brains
from mice inoculated with various genotypes of the Pru background were har-
vested and homogenized by using a Dounce homogenizer in 2 ml of sterile PBS
(30). All cyst counts were performed immediately after the isolation of brain
homogenates. In most experiments, 20 slides (10%) of each brain were scored for
cysts, and any deviation from this counting scheme was performed only in cases
when cyst numbers were low and additional slides were scored. Cysts were scored
under an inverted fluorescence phase-contrast microscope (Olympus CKX41) to
count GFP-positive (GFP) cysts at a magnification of
150, which provided the
highest sensitivity for the detection of GFP cysts. Average cyst size was mea-FIG. 1. Construction of the type II ku80 hxgprt genetic back-
ground. (A) Strategy for disrupting the KU80 gene in the parental Pru
strain via integration of the HXGPRT marker. Approximate locations
of PCR products using primer pairs to verify the genotype at the KU80
locus (not to scale) and the expected PCR product sizes are shown.
(Top agarose gel panel) PCR 1 and PCR 2 products: 17 randomly
selected clones isolated after selection (lanes 1 to 17), parental Pru
(lane 18), no template (lane 19), DNA size ladder (lane 20). Clones in
lanes 5, 9, and 10 appear negative for PCR 1 showing deletion of the
KU80 gene. (Bottom agarose gel panel) PCR 3: clones from lanes 5, 9,
and 10 (lanes 1 to 3), parental Pru (lane 4), no template (lane 5); PCR
4: clones from lanes 5, 9, and 10 (lanes 6 to 8), parental Pru (lane 9),
no template (lane 10). DNA size ladder (lane 11). A targeted KU80
knockout is positive for the PCR 2, PCR 3, and PCR 4 products and
negative for the PCR 1 product. Genotypes with an intact KU80 locus
are positive for PCR 1 and PCR 2 and negative for PCR 3 and PCR 4.
(B) Excision of the HXGPRT marker from the KU80 locus in the
Pruku80::HXGPRT strain. The strategy for excision of HXGPRT is
depicted with negative selection in 6TX after transfection with plasmid
pTPRC2. Approximate locations of PCR products using primer pairs
to verify genotype are depicted (not to scale). The expected PCR
product sizes are shown for a positive result. (Agarose gel panel) PCR
1 and PCR 5 products: 11 clones isolated after 6TX selection (lanes 1
to 11), parental Pru (lane 12), parental Pruku80::HXGPRT (lane 13),
DNA size ladder (lane 14). The Pruku80hxgprt strain is positive for
PCR 5 and negative for PCR 1 (lanes 1 to 11), the parental Pru strain
is positive for PCR 1 and negative for PCR 5 (lane 12), and the
parental Pruku80::HXGPRT strain is negative for PCR 1 (496-bp
product) and PCR 5 (lane 13).
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sured as a relative unit of diameter. Average cyst size was determined at a
magnification of 
150 by measuring bradyzoite diameter units (BDU). BDU
were determined for each randomly selected cyst by counting the number of
GFP bradyzoites residing in a direct line from one edge of the cyst wall to the
opposite edge of the cyst wall at the maximum point of the cyst diameter. BDU
were determined for 25 randomly selected cysts from each mouse brain tissue
sample. At least five mice were used to determine BDU for each parasite strain
tested. Cyst data samples were subjected to a Student t test and are represented
as means  the SEM. Differences in cyst burdens between groups of infected
mice were significant if the P value was 	0.05. Cysts were also evaluated using
confocal microscopy. Images were acquired using a Zeiss LSM 510 Meta laser
scanning confocal microscope equipped with a 20
 Plan Apo NA 0.75 objective
lens (Carl Zeiss Microimaging, Thornwood, NY). Confocal settings were set to
1 Airy unit (1.8-m optical section). A zoom setting of six generated a pixel size
of 0.15 by 0.15 m. LSM 510 software version 3.2 was used.
RESULTS
Generation of T. gondii strains Pruku80::HXGPRT and
Pruku80hxgprt. Alignments of the predicted type I (26) and
type II (TGME49_112510, 583.m05492 [www.toxodb.org] ver-
sion 4.0) KU80 loci revealed frequent strain specific nucleotide
polymorphisms. Plasmid pTPR1 was developed to function-
ally delete the type II KU80 gene. Multiple independent trans-
fections of various type II strains, selections, and screens of
more than 800 MPA resistant clones failed to identify a
targeted KU80 knockout in any type II strain.
We constructed plasmid pTPFC1 with the cytosine deami-
nase (CD) gene inserted 3 of the 3 KU80 target DNA flank
(Fig. 1A). Inclusion of the CD gene provided a more robust
selection strategy for double crossovers at the KU80 locus by
using negative selection to eliminate transformants that still
retained expression of CD by growth of the transfected
parasite population in 5-fluorocytosine (Fig. 1A). After con-
tinued attempts using the CD negative selection strategy, we
detected a low frequency of KU80 knockout clones
(Pruku80::HXGPRT) that were positive for PCR 2 and were
negative for PCR 1 that probes for the presence of the targeted
deletion in the KU80 gene (Fig. 1A, lanes 5, 9, and 10, top gel
panel). Three PCR 1-negative clones were then validated as
FIG. 2. Targeted gene replacement at the orotate phosphoribosyl-
transferase (OPRT) locus. (A) Strategy for disruption of OPRT by
double-crossover homologous recombination in type II strain
Pruku80hxgprt using plasmid pOPP and in type I strain
RHku80hxgprt using plasmid pOPT. Compared to plasmid
pOPP, plasmid pOPT contains seven single-nucleotide polymor-
phisms (indicated by “*”) in the 5 targeting DNA flank and three
nucleotide polymorphisms in the 3 targeting DNA flank. The PCR
strategy for genotype verification of deletion of OPRT is depicted (not
to scale). The expected PCR product sizes are shown for a positive
result. (Top agarose gel panel) PCR 1 and PCR 2 products: 6 clones
isolated after targeting type I OPRT deletion (lanes 1 to 6), 6 clones
isolated after targeting type II OPRT deletion (lanes 7 to 12), parental
type I RHku80hxgprt (lane 13), parental type II Pruku80hxgprt
(lane 14), no template (lane 15) DNA size ladder (lane 16). All six type
I clones and all six type II clones appear to be OPRT knockouts (PCR
1 negative and PCR 2 positive). Type I and type II clones were eval-
uated in PCR 3 and PCR 4 to verify integration of HXGPRT at the
deleted OPRT locus. (Bottom agarose gel panel) PCR 3 products: type
I clones (lanes 1 to 4), type II clones (lanes 5 to 8); PCR 4 products:
type I clones (lanes 9 to 12), type II clones (lanes 13 to 16); PCR 3 and
PCR 4 on parental type I RHku80hxgprt (lane 17), PCR 3 and PCR
4 on parental type II Pruku80hxgprt (lane 18), PCR 3 and PCR 4
using no template (lane 19), DNA size ladder (lane 20). (B) PFU
assays were performed at various times after transfection of pOPT in
the type I RHku80hxgprt (top) or after transfection of plasmid
pOPP into the type II Pruku80hxgprt (bottom) to determine the
gene replacement frequency at the OPRT locus based on the fraction
of parasites that exhibited resistance to MPA and grew with uracil
supplementation compared to the fraction of parasites that were re-
sistant to MPA without uracil supplementation (Table 2). The PFU
assays shown were sampled 25 days posttransfection with or without
uracil. All PFU assays contained MPA selection medium.
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targeted KU80 knockouts using PCR 3 and PCR 4 to demon-
strate precise 5 and 3 integration of HXGPRT at the deleted
KU80 locus (Fig. 1A, bottom gel panel). To delete the
HXGPRT marker from the Pruku80::HXGPRT strain, two
clones were transfected with plasmid pTPRC2, which is iden-
tical to plasmid pTPR1 but lacks the HXGPRT gene (Fig.
1B). 6TX-resistant parasite clones were obtained, and these
clones uniformly exhibited the genotype ku80 hxgprt based
on PCR analysis using PCR 1 and PCR 5 that was designed to
span the deleted region of KU80 and to demonstrate the tar-
geted deletion of the 2-kb HXGPRT marker (Fig. 1B).
Influence of DNA sequence homology on gene replacement
frequency at the OPRT locus. Disruption of de novo pyrimidine
synthesis induces uracil auxotrophy (23, 24). Here, the OPRT
locus was targeted for deletion to induce uracil auxotrophy as
a phenotype. Type II OPRT deletion was targeted using plas-
mid pOPP and type I OPRT deletion was targeted using
plasmid pOPT (Fig. 2A). OPRT knockouts were obtained in
type I and type II backgrounds based on the identification of
clones that were positive for PCR 2 and negative for PCR 1
that probes for the presence of the targeted deletion in the
OPRT gene (Fig. 2A, top gel panel). Using PCR 3 and PCR 4,
four of these clones from each strain type were then shown to
be targeted OPRT deletions based on precise 5 and 3 inte-
gration of the HXGPRT marker at the OPRT locus (Fig. 2A,
bottom gel panel).
The efficiency of gene targeting at the OPRT locus in the
type I versus the type II ku80 hxgprt strain was measured
using target DNA flanks with a strain-specific DNA homology
of 100% (Fig. 2A) (Table 2). PFU assays performed on the
MPA-selected population of parasites at 18 and again at 25
days posttransfection of the targeting plasmids revealed that
targeted disruption of OPRT created the uracil auxotroph phe-
notype at a high frequency in both the type I and the type II
ku80 hxgprt strains (Fig. 2B). The gene targeting frequency
at the OPRT locus was found to be slightly higher in the type
II strain Pruku80hxgprt (99.8%  0.1%) compared to the
type I strain RHku80hxgprt (92.9%  1.5%) (Table 2).
Naturally occurring nucleotide polymorphisms present
within the 5 and 3 noncoding DNA between type I and type
II strains enabled a test of homology requirements necessary
for efficient gene targeting at the OPRT locus in T. gondii (Fig.
2A). These nucleotide polymorphisms divided the 5 target
flank into segments of 94, 162, 53, 127, 39, 240, 88, and 247 bp
of homology and the 3 target flank into segments of 530, 22,
359, and 208 bp of homology (sequence alignments between
type I and type II OPRT are not shown). Type I targeting
plasmid pOPT with 7 nucleotide mismatches in the 5 target
DNA flank and 3 mismatches in the 3 target DNA flank
relative to type II was inefficient in targeting gene deletion at
the type II OPRT locus (Table 2).
Targeted disruption of the key enzymes of the pyrimidine
salvage pathway. Disruption of UPRT was used to measure
gene replacement efficiency in strain Pruku80hxgprt (26).
The frequency of gene replacement at the UPRT locus was
determined at different time points after transfection of plas-
mid pUPRP by plating equal numbers of parasites either in
MPA or in MPA plus FUDR selection. The nonreverting
Pruku80uprt::HXGPRT genotype was also confirmed in
several MPA resistant clones (data not shown). The fre-
quency of gene replacement at the UPRT locus in strain
Pruku80hxgprt was found to be only 3.3% 0.4% at 10 days
posttransfection, but this frequency steadily increased to
98.2%  1.1% by day 32 posttransfection (Table 3). In con-
trast, the gene replacement efficiency in the parental Pru strain
was 	0.10% at 32 days postinfection (Table 3).
It is currently unknown whether the two critical enzymes of
the pyrimidine salvage pathway (23) (UPRT and uridine phos-
phorylase [UP]) are required for cyst development and latent
T. gondii infection. To complete a genetic dissection of the
major pyrimidine salvage activities in the type II T. gondii and
to assess the potential role of the salvage pathway in cyst
development, we deleted the UP gene using plasmid pUPP
(data not shown) (Table 1). We found that 23 of 24 randomly
selected MPA-resistant clones (96%) had the UP gene deleted.
Efficient targeted excision of the HXGPRT selectable marker
from Pruku80 mutant strains. HXGPRT was targeted for dele-
tion from the OPRT locus in strain Pruku80oprt::HXGPRT
using plasmid pOPPC and negative selection in 6TX. Strain
Pruku80oprt was easily isolated and validated by PCR analysis
(data not shown) (Table 1).
Pruku80hxgprt stably maintains the ability to develop
cysts and chronic infection in mice. We observed no significant
difference (P  0.20) between the in vitro intracellular repli-
cation rates of strain Pruku80hxgprt (14.2  0.50 parasites/
vacuole) compared to the parental Pru strain (15.0  0.15 par-
asites/vacuole) (Table 4). The type II strain Pruku80hxgprt
stably maintained the ability to develop brain tissue cyst bur-
dens in mice after more than 16 months of continuous in vitro
culture. Brain tissue cysts obtained from mice infected with the
strain Pruku80hxgprt revealed a cyst wall structure (Fig.
3A), as well as the expected bradyzoite stage-specific expres-
TABLE 2. Gene replacement frequency at the OPRT locus in type
I and type II KU80 knockouts
Transfected strain Plasmida Dayassayed
Gene replacement
(%) at the OPRT
locus
Expt 1 Expt 2
RHku80hxgprt pOPT 18 92.1 93.0
RHku80hxgprt pOPT 25 91.4 94.3
Pruku80hxgprt pOPP 18 98.8 99.3
Pruku80hxgprt pOPP 25 99.7 99.8
Pruku80hxgprt pOPT 18 13.2 12.4
Pruku80hxgprt pOPT 25 10.6 14.9
a pOPT is derived from type I RH, and pOPP is derived from type II Pru.
TABLE 3. Gene replacement frequency at the UPRT locus
Transfected strain Plasmid Dayassayed
Gene replacement
(%) at the UPRT
locus
Expt 1 Expt 2
Pruhxgprt pUPRP 25 0.03 0.00
Pruhxgprt pUPRP 32 0.08 0.00
Pruku80hxgprt pUPRP 10 3.74 2.90
Pruku80hxgprt pUPRP 18 46.7 55.4
Pruku80hxgprt pUPRP 25 75.9 82.1
Pruku80hxgprt pUPRP 32 97.1 99.2
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sion of GFP (Fig. 3B and C) (60). In contrast, GFP expression
was not detected in strain Pruku80hxgprt during in vitro
culture of the tachyzoite stages (data not shown). In addition,
brain cyst burdens in C57BL/6 mice at 3 weeks postinfection
with strain Pruku80hxgprt (942 184) were essentially iden-
tical (P  0.70) to the brain cyst burdens observed after infec-
tion with the parental Pru strain (1,065  262) (Fig. 3D).
Furthermore, cyst sizes in strain Pruku80hxgprt (13.0  0.46
BDU) were essentially identical (P  0.63) to the cyst sizes
measured in the parental Pru strain (13.3  0.47 BDU) (Fig.
TABLE 4. Intracellular replication rate of selected strains used in this study
Strain (reference) Mean no. of parasites pervacuolea  SEM
P (compared to the control strain)b
P Significance Control straingenotype
Pruku80gra4::HXGPRT 14.1  0.48 0.74 NS ku80::HXGPRT
Pruku80gra6::HXGPRT 13.9  0.29 1 NS ku80::HXGPRT
Pruku80gra6gra4::HXGPRT 13.2  0.14 0.09 NS ku80::HXGPRT
Pruku80uprt::HXGPRT 14.2  0.13 0.33 NS ku80::HXGPRT
Pruku80tgd057::HXGPRT 15.2  0.31 0.02 S ku80::HXGPRT
Pruku80rop4/7::HXGPRT 14.9  0.20 0.03 S ku80::HXGPRT
Pruku80::HXGPRT 13.9  0.31 ND
Pruhxgprt (parental) (60) 15.0  0.17 ND
Pruku80hxgprt 14.2  0.57 0.20 NS hxgprt (parental)
Pruku80gra4hxgprt 14.5  0.36 0.70 NS ku80 hxgprt
Pruku80gra6hxgprt 13.8  0.23 0.51 NS ku80 hxgprt
Pruku80gra6gra4hxgprt 13.5  0.36 0.36 NS ku80 hxgprt
a Parasites per vacuole were scored after 45 h of intracellular replication.
b To determine the P value, strains were matched for the presence or absence of HXGPRT. S, significant; NS, not significant; ND, not determined.
FIG. 3. The Pruku80hxgprt strain elicits GFP cysts and chronic and/or latent infection in genetically susceptible C57BL/6 mice. (A to E)
C57BL/6 mice were infected by intraperitoneal inoculation of 200 of the tachyzoites of Pruku80hxgprt strain or the parental Pru strain. (A, B,
and C) An example of a cyst observed at 5 weeks postinfection of C57BL/6 mice with strain Pruku80hxgprt. (A) Bright-field laser confocal
microscopy with light collected from a 1.8-m-thick section. (B) GFP fluorescence from the same sample shown in panel A. (C) Merge of panels
A and B. (D) Brain cyst burdens were measured in the parental Pru strain and the Pruku80hxgprt strain at 3 weeks postinfection of C57BL/6
mice. (E) The average size of brain cysts was determined in the parental Pru strain and the Pruku80hxgprt strain at 3 weeks postinfection of
C57BL/6 mice as a relative measure of cyst diameter (BDU [see Materials and Methods]). (F) C57BL/6 mice were perorally infected with 10 cysts
of the Pruku80hxgprt strain. A survival curve of C57BL/6 mice (n  6) infected perorally with 10 brain cysts of strain Pruku80hxgprt (solid
squares), or uninfected mice (n  4) inoculated with PBS (solid circles).
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3E). Finally, peroral infection of the genetically susceptible
C57BL/6 background with 10 brain cysts of strain
Pruku80hxgprt caused an acute infection with morbidity,
and infected mice recovered and then developed the expected
chronic infection that eventually led to mortality (Fig. 3F).
Deletion of the KU80 gene in strain Pruku80hxgprt did not
lead to any significant defects in regard to the intracellular
growth rate, the development of brain cyst burdens, the cyst
size, or the establishment of a chronic or latent infection.
Targeted deletions at the GRA4, GRA6, ROP4/7, and tgd057
loci. To assess the interplay of host response and cyst devel-
opment, targeted deletions were developed at the four gene
loci known to encode CD8 T cell epitopes that elicit corre-
sponding antigen-specific CD8 T cell populations during T.
gondii infection. Targeting plasmids pGRA4P, pGRA6P,
pROP4/7P, and pTGD057P were used to develop mutant
strains with deletions of the GRA4, GRA6, ROP4/7, or tgd057
loci. Plasmids pGRA4PC and pGRA6PC were then used to
target the removal of HXGPRT from the disrupted GRA4 and
GRA6 loci in 6TX-negative selections. Finally, the GRA4
and GRA6 strains with HXGPRT deleted were used to de-
velop several mutant strains with targeted deletion of two
genetic loci (ku80 gra6 gra4::HXGPRT, ku80 gra4
tgd057::HXGPRT, and ku80 gra6 tgd057::HXGPRT)
(Table 1).
Determination of the replication rate of mutant strains in
vitro. None of the mutant strains examined exhibited any sig-
nificant decrease in their intracellular growth rate in a 45 h
growth assay (parasites per vacuole) compared to the control
strain matched for the presence or absence of HXGPRT (Table
4). Two of the mutant strains, ku80 tgd057::HXGPRT (P 
0.020) and ku80 rop4/7::HXGPRT (P  0.032), were found
to exhibit a significant increase in the number of parasites per
vacuole in the 45-h in vitro growth assay.
Measurement of brain tissue cyst burdens in mice infected
with mutant strains. Cyst development was examined in the
genetically susceptible C57BL/6 murine background that exhibits
higher cyst burdens, reactivation, and chronic infection compared
to the genetically resistant BALB/c murine background (30, 45,
56). Cyst burdens measured at 3 weeks postinfection of C57BL/6
mice were 462  111 for the Pruku80::HXGPRT strain and
942  184 for the Pruku80hxgprt strain (Fig. 4A; P  0.0499).
Nonetheless, all of the knockouts reported in the present study
were developed in the Pruku80hxgprt parent strain that is nor-
mal in regard to intracellular replication rate, cyst development,
and cyst burdens (Fig. 3). The mutant strains developed in the
FIG. 4. Brain cyst burdens measured at 3 weeks postinfection.
C57BL/6 or CBA mice were infected by intraperitoneal inoculation of
200 tachyzoites of mutant or parental strains. (A, B, and C) Brain cyst
burdens in C57BL/6 mice. (A) Cyst burdens were measured at 3 weeks
postinfection of C57BL/6 mice infected with the strain genotypes
ku80::HXGPRT (6 mice), ku80 hxgprt (6 mice), ku80
uprt::HXGPRT (5 mice), ku80 tgd057::HXGPRT (6 mice), and
ku80 rop4/7::HXGPRT (6 mice). (B) Cyst burdens were measured
at 3 weeks postinfection of C57BL/6 mice infected with the strain
genotypes ku80 hxgprt (6 mice), ku80 gra4::HXGPRT (6 mice),
ku80 gra6::HXGPRT (6 mice), ku80 gra4 hxgprt (4 mice), and
ku80 gra6 hxgprt (4 mice). (C) Cyst burdens were measured at 3
weeks postinfection of C57BL/6 mice infected with the strain geno-
types ku80 hxgprt (6 mice), ku80 gra4 tgd057::HXGPRT (6
mice), ku80 gra6 tgd057::HXGPRT (6 mice), ku80 gra6
gra4::HXGPRT (6 mice), and ku80 gra6 gra4 hxgprt (4 mice).
(D) Brain cyst burdens in CBA mice. Cyst burdens were measured at
3 weeks postinfection of CBA mice infected with strain genotypes
ku80 hxgprt (6 mice), ku80 gra4::HXGPRT (6 mice), ku80
gra6::HXGPRT (6 mice), and ku80 tgd057::HXGPRT (4 mice).
Cyst data samples were subjected to a Student t test and are repre-
sented as the means  the SEM. Cyst burdens determined in mutant
strains were compared to cyst burdens in the parental ku80 hxgprt
strain to establish significance (P 	 0.05).
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Pruku80hxgprt parent share the identical disrupted KU80 locus
and differ only in regard to the presence of HXGPRT that is
inserted at the gene locus targeted for deletion. Consequently,
several gene knockouts developed in the Pruku80hxgprt strain
using HXGPRT selection were subsequently deleted of HXGPRT
to allow more optimal assessment of phenotypes in comparison to
the parental Pruku80hxgprt strain.
Several mutant strains, including Pruku80up::hxgprt
(data not shown), Pruku80uprt::hxgprt (P  0.75), Pru
ku80rop4/7::hxgprt (P 0.33), and Pruku80tgd057::hxgprt
(P  0.11), exhibited no significant difference in cyst burdens
compared to the parental Pruku80hxgprt strain at 3 weeks
postinfection (Fig. 4A). In contrast, at 3 weeks postinfection of
C57BL/6 mice, a 91% reduction (P  0.0010) in cyst burden
was observed in the gra6 mutant with HXGPRT (ku80
gra6::HXGPRT) and a 91% reduction (P  0.0010) in cyst
burden was observed in the gra4 mutant with HXGPRT
(ku80 gra4::HXGPRT) (Fig. 4B). Similarly, a 93% reduction
(P  0.0051) in cyst burden was observed in the gra6 mutant
with HXGPRT deleted (ku80 gra6 hxgprt) and an 89%
reduction (P  0.0066) in cyst burden was observed in the
gra4 mutant with HXGPRT deleted (ku80 gra4 hxgprt)
(Fig. 4B). Double mutants involving the GRA4 and/or the
GRA6 loci were also examined for cyst development
in C57BL/6 mice. Although the Pruku80gra4tgd057::
HXGPRT (91% reduction; P  0.0009) and Pruku80
gra6tgd057::HXGPRT (86%; P  0.0032) mutant strains
revealed similar reductions in cyst burden (Fig. 4C) compared
to the gra4 and gra6 single mutants with or without the
HXGPRT marker (Fig. 4B), the double-mutant strain
Pruku80gra6gra4::HXGPRT revealed a markedly more se-
vere defect in cyst burdens at 3 weeks postinfection (99%
reduction; P  0.0005) (Fig. 4C). This more significant defect
in cyst burden in the ku80 gra6 gra4::hxgprt double mutant
was then verified by construction of the ku80 gra6 gra4
hxgprt strain that exhibited a 99.8% reduction (P 0.0037) in
cyst burden (Fig. 4C). Collectively, these results demonstrate a
significant defect in the development of brain cyst burdens in
mutant strains with GRA4 and/or GRA6 deleted in C57BL/6
mice.
We also measured cyst burdens in the CBA murine (H-2Kk)
background because the four currently characterized CD8 T
cell epitopes encoded by the GRA4, GRA6, ROP7, and tgd057
genes are not recognized by the H-2Kk-restricted CBA back-
ground. In the CBA murine background a 77% reduction (P
0.018) in cyst burden was observed in the gra6 mutant and an
87% reduction (P  0.011) in cyst burden was observed in the
gra4 mutant at 3 weeks postinfection (Fig. 4D). In contrast,
no significant difference in cyst burden was observed in the
tgd057 mutant (P  0.099).
In addition, the cyst burdens for many of the mutant strains
were also measured at 5 weeks postinfection of C57BL/6 mice.
The Pruku80::HXGPRT (P  0.28), Pruku80uprt::HXGPRT
(P  0.25), and Pruku80tgd057::HXGPRT (P  0.90) strains
exhibited no significant difference in cyst burdens compared to
the Pruku80hxgprt strain at 5 weeks postinfection (Fig. 5A). In
contrast, the Pruku80rop4/7::HXGPRT mutant exhibited a
70% reduction in cyst burden at 5 weeks postinfection (P 
0.0089) (Fig. 5A). Significant reductions in cyst burdens com-
pared to the parental ku80 hxgprt strain were also observed in
FIG. 5. Brain cyst burdens measured at 5 weeks postinfection.
C57BL/6 mice were infected by intraperitoneal inoculation of 200
tachyzoites of mutant or parental strains. (A, B, and C) Brain cyst
burdens in C57BL/6 mice. (A) Cyst burdens were measured at 5 weeks
postinfection of C57BL/6 mice infected with the strain genotypes
ku80::HXGPRT (6 mice), ku80 hxgprt (6 mice), ku80
uprt::HXGPRT (6 mice), ku80 tgd057::HXGPRT (6 mice), and
ku80 rop4/7::HXGPRT (6 mice). (B) Cyst burdens were measured
at 5 weeks postinfection of C57BL/6 mice infected with the strain
genotypes ku80 hxgprt (6 mice), ku80 gra4::HXGPRT (6 mice),
ku80 gra6::HXGPRT (6 mice), ku80 gra4 hxgprt (4 mice), and
ku80 gra6 hxgprt (4 mice). (C) Cyst burdens were measured at 5
weeks postinfection of C57BL/6 mice infected with the strain geno-
types ku80 hxgprt (6 mice), ku80 gra4 tgd057::HXGPRT (6
mice), ku80 gra6 tgd057::HXGPRT (6 mice), ku80 gra6
gra4::HXGPRT (6 mice), and ku80 gra6 gra4 hxgprt (4 mice).
Cyst data samples were subjected to a Student t test and are repre-
sented as means  the SEM. Cyst burdens determined in mutant
strains were compared to cyst burdens in the parental ku80 hxgprt
strain to establish significance (P 	 0.05).
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each of the gra4 and gra6 mutant strains examined at 5
weeks postinfection (Pruku80gra4::HXGPRT [P  0.0020],
Pruku80gra6::HXGPRT [P  0.0029], Pruku80gra4hxgprt
[P  0.011], Pruku80gra6hxgprt [P  0.0087], Pruku80
gra4tgd057::HXGPRT [P  0.0015], Pruku80gra6tgd057::
HXGPRT [P  0.0010], Pruku80gra6gra4::HXGPRT [P 
0.0007], Pruku80gra6gra4hxgprt [P  0.0040]) (Fig. 5B
and C).
Complementation of the gra4 and gra6mutants. To more
clearly establish that the defect in cyst burdens observed in the
gra4 and gra6 mutant strains was due to the deletion of
GRA protein function, we complemented the gra4 and gra6
mutants by reinserting a functional allele of the deleted GRA
gene. Rather than simply recreating the parental strain with an
intact GRA locus, we complemented the ku80 gra4 hxgprt
and the ku80 gra6 hxgprt mutants by targeting the insertion
of the GRA coding region and the HXGPRT marker into the
UPRT locus, deleting the coding region of the UPRT gene (Fig.
6A and B). This strategy was based on our observation of
normal cyst burdens in the ku80 uprt::hxgprt mutant (Fig.
4A). In addition, by design we deleted the extremely strong
GRA4 and GRA6 transcriptional promoters and their 5 tran-
scribed, untranslated region (5 GRA UTRs), and via homol-
ogous recombination placed the GRA protein coding region(s)
under the control of the endogenous UPRT locus 5UTR
which ranks at the  78% for expression level percentile (mi-
croarray data [www.toxodb.org]) (Fig. 6). In contrast, the rel-
ative expression level percentile ranking is  94.2% for the
endogenous GRA4 locus and 99.2% for the endogenous
GRA6 locus. Parasites transfected with the pGRA4X and
pGRA6X complementation cassettes were selected in MPA
for 10 days then the population was selected in FUDR. Com-
plemented clones were examined using a PCR strategy (Fig. 6)
and correctly targeted clones with the genotypes ku80 gra4
uprt::gra4coding region  3UTR HXGPRT and ku80 gra6
uprt::gra6coding region  3UTR HXGPRT were validated
(Fig. 6).
Two independent cloned isolates of each complemented
strain were examined for cyst burden in C57BL/6 mice at 3
weeks postinfection. GRA4 complemented clones exhibited a
402 to 426% increase in cyst burdens compared to the gra4
mutant strain also lacking HXGPRT (GRA4, P  0.0010 and
P  0.024) (Fig. 7). GRA6 complemented clones exhibited a
291 to 352% increase in cyst burdens compared to the gra6
mutant strain also lacking HXGPRT (GRA6, P  0.032 and
P  0.031) (Fig. 7).
FIG. 6. Genetic strategy for complementation of the gra4 and
gra6 deletion mutants. The coding region of the deleted GRA gene
and the associated GRA 3UTR was placed under regulatory control
of the endogenous UPRT locus 5UTR. (A) Plasmid pGRA4X was
transfected into the Pruku80gra4hxgprt strain, and parasites were
selected in MPA and then selected in FUDR to select for the uprt
phenotype. Clones isolated from this selection were examined using
PCR 1, PCR 2, and PCR 3 to verify precise integration of the GRA4
coding region at the deleted uprt locus. PCR 1 measures correct 5
integration, PCR 2 measures correct 3 integration, and PCR 3 mea-
sures the presence of the GRA4 coding region. (Agarose gel panel)
PCR 1, PCR 2, and PCR 3 products: DNA size ladder (lane 1), PCR
1 from 3 complemented clones (lanes 2 to 4), PCR 2 from 3 comple-
mented clones (lanes 5 to 7), PCR 3 from 3 complemented clones
(lanes 8 to 10), PCR 1 from parental Pruku80gra4hxgprt (lane 11),
PCR 2 from parental Pruku80gra4hxgprt (lane 12), PCR 3 from
parental Pruku80gra4hxgprt (lane 13), PCR 3 from
Pruku80hxgprt (lane 14). (B) Plasmid pGRA6X was transfected into
the Pruku80gra6hxgprt strain, and parasites were selected in MPA
and then selected in FUDR to select for the uprt phenotype. Clones
isolated from this selection were examined using PCR 4, PCR 5, and
PCR 6 to verify precise integration of the GRA6 coding region at the
deleted uprt locus. PCR 4 measures correct 5 integration, PCR 5
measures correct 3 integration, and PCR 6 measures the presence of
the GRA4 coding region. (Agarose gel panel) PCR 4, PCR 5, and PCR
6 products: DNA size ladder (lane 1), PCR 4 from three comple-
mented clones (lanes 2 to 4), PCR 5 from three complemented clones
(lanes 5 to 7), PCR 6 from three complemented clones (lanes 8 to 10),
PCR 4 from parental Pruku80gra6hxgprt (lane 11), PCR 5 from
parental Pruku80gra6hxgprt (lane 12), PCR 6 from parental
Pruku80gra6hxgprt (lane 13), PCR 6 from Pruku80hxgprt
(lane 14).
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DISCUSSION
Type II isolates of T. gondii represent a prevalent strain type
infecting humans and causing life-long infections characterized
by the presence of the bradyzoite stage encysted tissue cyst.
Previously, targeted genetic dissection of type II T. gondii
strains was limited by inefficient homologous recombination
pathways relative to highly efficient pathways for random inte-
gration of targeting episomes. By eliminating the dominant
pathway of nonhomologous recombination via knockout and
functional disruption of the KU80 gene (26), we now report a
new genetic model that enables efficient gene replacements
and the reliable development of targeted gene deletions in type
II T. gondii.
The Pruku80hxgprt strain exhibited efficient gene target-
ing at the UPRT locus, at the OPRT locus, and at all other
targeted loci. Efficient gene targeting was demonstrated to be
dependent on perfect DNA sequence homology. We success-
fully targeted seven genetic loci for deletion (UPRT, UP,
OPRT, GRA4, GRA6, ROP4/7, and tgd057), we retargeted the
deletion of HXGPRT inserted at three disrupted loci (OPRT,
GRA4, GRA6), we constructed three mutant strains with two
targeted gene deletions (gra4 gra6, gra4 tgd057, and
gra6 tgd057), and we functionally complemented the GRA4
and GRA6 knockouts. These results show that the type II
ku80 hxgprt genetic background is amenable for rapid and
reliable development of targeted gene deletions, and other
more complex genetic manipulations involving sequential tar-
geting, removal of HXGPRT at the deleted locus, and retar-
geting using HXGPRT. The ability of the Pruku80hxgprt
strain to develop cyst burdens and latent infection was main-
tained after long-term in vitro culture or multiple genetic ma-
nipulations. In addition, the Pruku80hxgprt strain retained a
normal intracellular replication rate compared to the parental
Pru strain, and this strain also retains normal acute virulence in
mice (data not shown). The type I KU80 knockout strain
RHku80hxgprt retains a normal intracellular replication
rate, acute virulence in mice (26), and this strain also exhibits
an identical profile of gene expression during the cell cycle as
parental RH (3). Collectively, these results support the
Pruku80hxgprt genetic background as an improved genetic
model for dissecting type II T. gondii biology.
Type II mutants deleted in pyrimidine salvage activities for
UPRT and UP were not defective in cyst development, dem-
onstrating that pyrimidine salvage through the UPRT or UP
enzyme activities is not required for cyst development or the
establishment of latent infection. These results suggest that de
novo pyrimidine synthesis is functional and essential during
bradyzoite stage conversion, cyst development, and latent in-
fection.
We examined the hypothesis that host CD8 T cell re-
sponses directed against specific parasite antigens containing
CD8 T cell epitopes (GRA4, GRA6, ROP7, and tgd057) (5,
27, 42, 68) may influence cyst development. Our analysis was
hindered by the low cyst burdens (	60 cysts per brain) that we
observed in the H-2Ld-restricted BALB/c background. The
H-2Ld-restricted BALB/c background is genetically resistant to
infection and establishes a latent infection with reduced cyst
burdens compared to genetically susceptible murine back-
grounds such as C57BL/6, which exhibit higher cyst burdens,
reactivation, and chronic infection (30, 45, 56). Recent obser-
vations suggest that infection of genetically susceptible
C57BL/6 mice with the Pru strain produces the highest brain
tissue cyst burden at 3 weeks postinfection (56), then cysts
rupture (reactivate) and are lost at a higher rate than any
potential rate of cyst reformation during chronic infection.
Immune control of type II T. gondii infection has been pro-
posed to be dependent on type II strain-specific H-2Ld-re-
stricted cytotoxic T cells (35). This hypothesis is supported by
the identification of the immunodominant and protective de-
capeptide HF10 epitope within the type II GRA6 protein that
is presented in the context of the H-2Ld major histocompati-
bility complex class I molecule (5).
The previously identified GRA4, GRA6, and ROP7 CD8 T
cell epitopes are H-2Ld-restricted (5, 27), whereas the tdg057
CD8 T cell epitope is H-2Kb restricted. Consequently, in
C57BL/6 mice a CD8 T cell response is mounted against the
known tdg057 epitope (68), but not against the known GRA4,
GRA6, or ROP7 epitopes. At 3 weeks postinfection of
C57BL/6 mice, we observed no significant differences in cyst
burdens in either the rop4/7 or the tgd057 mutants com-
pared to the ku80 hxgprt parent. The absence of CD8 T
cell response to the tgd057 epitope, as well as the loss of tgd057
protein function in the tgd057 mutant, did not significantly
affect cyst burdens. Similarly, the absence of CD8 T cell
response to ROP7 in both the parental strain and the rop4/7
mutant, along with the loss of ROP4/7 protein functions, did
not significantly affect cyst burdens at 3 weeks postinfection. In
FIG. 7. Cyst burdens are significantly increased in the GRA-com-
plemented strains. C57BL/6 mice were infected by intraperitoneal
inoculation of 200 tachyzoites of mutant parental or complemented
strains. Cyst burdens were measured at 3 weeks postinfection of
C57BL/6 mice infected with the strains Pruku80gra4::HXGPRT (6
mice), Pruku80gra4uprt::gra4coding region  3UTRHXGPRT (clone 1,
4 mice, and clone 2, 4 mice), Pruku80gra6::HXGPRT (6 mice),
Pruku80gra6uprt::gra6coding region  3UTRHXGPRT (clone 1, 4
mice, and clone 2, 4 mice). Cyst data samples were subjected to a
Student t test and are represented as means  the SEM. Cyst burdens
determined in complemented strains were compared to cyst burdens in
the parental gra strain to establish significance (P 	 0.05).
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contrast, while the CD8 T cell response to the GRA4 and
GRA6 epitopes is absent in the parental strain in the C57BL/6
murine background, the deletion of the GRA4 (gra4) and
GRA6 (gra6) genes markedly reduced cyst burdens indepen-
dently of any potential CD8 T cell response to the known
epitopes within these GRA proteins. However, we cannot
conclusively rule out the possibility that the GRA4 and/or
GRA6 genes encode as-yet-uncharacterized H-2Kb-restricted
epitopes. We also observed a significant defect in cyst burdens
in the gra4 and gra6 mutants in the CBA murine back-
ground (H-2Kk-restricted). These results suggest that the
GRA4 and GRA6 proteins directly mediate functions neces-
sary for the development of normal cyst burdens, rather than
cyst development being strictly dependent on the host response
to these proteins.
Previous studies have also reported defects in cyst develop-
ment following gene disruption in type II strains. Disruption of
the SRS9 gene or the SAG2CDXY gene locus revealed a phe-
notype of normal cyst burdens at 4 weeks postinfection, and
then reduced cyst burdens were observed later during latent
infection (41, 55). Disruption of a pseudouridine synthase ho-
mologue (PUS1) revealed a phenotype of slightly smaller cyst
size and slightly increased cyst burdens (1). Targeted disrup-
tion of the heat shock protein BAG1 gene (6, 69) resulted in a
minor defect in cyst development. A significant defect in cyst
burden was observed at 5 weeks postinfection in the rop4/7
mutant. Interestingly, the rop4/7 mutant and the tgd057
mutant exhibited an increase in their in vitro growth rate. The
recently reported type II GRA15 knockout was also reported
to exhibit an increased growth rate in vitro (54).
Cross-linking studies suggest that a multimeric protein com-
plex of GRA2, GRA4, and GRA6 exists within the nanotubu-
lar network of membranes within the parasitophorous vacuole
space (43). However, a recent study of protein interactions
using a more comprehensive panel of HA-FLAG-tagged GRA
proteins did not reveal a direct interaction of GRA2, GRA4,
and GRA6 in the membrane fraction (8). Disruption of GRA6
in type I tachyzoites revealed an altered intravacuolar network
of membranes characterized by small vesicles instead of elon-
gated nanotubules (47). The N terminus of GRA6 was also
recently shown to be a critical domain in interacting with neg-
atively charged lipids and is necessary for association of the
protein with the vacuolar membranous network of nanotubules
(28).
Type II mutants with GRA4 or GRA6 deleted exhibited
drastically reduced cyst burdens during T. gondii infection. The
defect in cyst development in these strains was independent of
the presence or absence of HXGPRT. Thus, these GRA pro-
teins appear to be involved in some aspect of cyst development
that significantly reduces the likelihood of cyst formation
rather than completely abrogating the parasites biological abil-
ity to convert to the bradyzoite stage and create a tissue cyst.
Complementation of the gra4 and gra6 mutants using a
functional allele of the corresponding GRA protein signifi-
cantly restored cyst burdens. However, cyst burdens were not
completely restored to the expected levels when GRA4 and
GRA6 expression was placed under regulatory control of the
UPRT locus. The relative strengths of the GRA4 and GRA6
promoters (GRA4, 94.2%; GRA6, 99.2% [www.toxodb
.org]) are significantly higher than that of the UPRT locus
(78%) used in the complementation study. These observa-
tions suggest that an extremely high level of expression of
GRA4 and GRA6 may be necessary for the development of
normal cyst burdens.
A more severe defect in cyst burden in the
ku80gra6gra4::HXGPRT and the ku80 gra6 gra4
hxgprt mutants compared to mutants with single deletions of
GRA4 or GRA6 suggests that GRA4 and GRA6 most likely
play independent functional roles required for cyst develop-
ment during infection. Ultrastructural localization is also con-
sistent with the likelihood of independent roles for GRA4 and
GRA6 in cyst development since, while GRA4 is abundant in
the tachyzoite stage, PV it is not detectable in the bradyzoite
stage cyst wall, whereas GRA6 is easily detected in both stages
(21). Since the cyst wall structure is thought to arise directly
from modifications to the PVM during tachyzoite to bradyzoite
conversion (59, 67), the function of GRA4 in cyst development
is likely to be exerted prior to or during formation of the cyst
wall.
Our study did not specifically address the mechanisms by
which GRA4 or GRA6 influence cyst development. With the
exception of uracil auxotrophy of the oprt mutants, no signif-
icant decreases were observed in the in vitro replication rate of
any of the mutants isolated in the present study. The defect in
cyst burden in the gra4 and gra6 mutants may be due to a
more successful innate or adaptive host response that sup-
presses parasite burden or dissemination necessary for devel-
opment of brain tissue cysts. Alternatively, GRA4 and GRA6
may play a direct role in parasite biology associated with the
probability of successful tachyzoite to bradyzoite conversion or
cyst development. Additional studies are therefore necessary
to assess acute virulence, parasite tissue burdens, dissemina-
tion patterns, and host response during infection to further
gauge potential mechanisms underlying the defect in cyst de-
velopment in the gra4 and gra6 mutants.
The GRA protein family is extremely interesting because
they are a remarkable family of highly expressed and compart-
mentalized proteins restricted thus far to the cyst-forming par-
asites Toxoplasma and Neospora (49). No identifiable ortholog
can be discerned even in closely related Conoidasida such as
Cryptosporidium or Eimeria or Aconoidasida such as Plasmo-
dium, which do not form tissue cysts (10). Our results suggest
that in addition to GRA4 and GRA6 other members of the
prominent GRA protein family may also play critical roles in
biology underlying successful cyst development and latent in-
fection.
The type II ku80 hxgprt strain developed in the present
study provides a reliable genetic model for targeted genetic
dissection of parasite biology occurring during T. gondii infec-
tion. The ability to now control both parasite genes and host
cell genes can reveal the complex interplay of parasite biology
and host response during T. gondii infection. These genetic
approaches will accelerate the development of improved strat-
egies for vaccines, immunological interventions, and other
therapeutics. Targeted genetic approaches using a type II
ku80 hxgprt genetic background has the immediate poten-
tial to functionally reveal parasite genes playing critical biolog-
ical roles that, when intercepted during in vivo infection, block
parasite development, pathogenesis, or transmission.
1204 FOX ET AL. EUKARYOT. CELL
ACKNOWLEDGMENTS
We are grateful to numerous Toxoplasma research laboratories that
provided helpful advice and suggestions during the course of this study.
This project was made possible by the work of the developers of the
Toxoplasma gondii Genome Resource (at www.ToxoDB.org), and their
work is gratefully acknowledged. ToxoDB, PlasmoDB, and EuPathDB
are part of the National Institutes of Health/National Institute of
Allergy and Infectious Disease (NIH/NIAID)-funded Bioinformatics
Resource Center. Type II strains were kindly provided by John
Boothroyd (Stanford University), Jeroen Saeij (Massachusetts Insti-
tute of Technology), and Elmer Pfefferkorn (Dartmouth College). This
study was supported by the use of facilities that were provided by the
Imaging Shared Resource of the Dartmouth-Hitchcock Norris Cotton
Cancer Center.
L.M.R. was a predoctoral trainee on NIH training grant
T32AI007519 on Host-Microbe Interactions. This study was supported
by the NIH (grant AI039454 to L.M.W. and grants AI41930, AI073142,
AI075931, and AI091461 to D.J.B.).
REFERENCES
1. Anderson, M. Z., J. Brewer, U. Singh, and J. C. Boothroyd. 2009. A pseu-
douridine synthase homologue is critical to cellular differentiation in Toxo-
plasma gondii. Eukaryot. Cell 8:398–409.
2. Beck, J. R., et al. 2010. A novel family of Toxoplasma IMC proteins displays
a hierarchical organization and functions in coordinating parasite division.
PLoS Pathog. 6:e1001094.
3. Behnke, M. S., et al. 2010. Coordinated progression through two subtran-
scriptomes underlies the tachyzoite cycle of Toxoplasma gondii. PLoS One
5:e12354.
4. Bierly, A. L., W. J. Shufesky, W. Sukhumavasi, A. E. Morelli, and E. Y.
Denkers. 2008. Dendritic cells expressing plasmacytoid marker PDCA-1 are
Trojan horses during Toxoplasma gondii infection. J. Immunol. 181:8485–
8491.
5. Blanchard, N., et al. 2008. Immunodominant, protective response to the
parasite Toxoplasma gondii requires antigen processing in the endoplasmic
reticulum. Nat. Immunol. 9:937–944.
6. Bohne, W., et al. 1998. Targeted disruption of the bradyzoite-specific gene
BAG1 does not prevent tissue cyst formation in Toxoplasma gondii. Mol.
Biochem. Parasitol. 92:291–301.
7. Boothroyd, J. C., and J. F. Dubremetz. 2008. Kiss and spit: the dual roles of
Toxoplasma rhoptries. Nat. Rev. Microbiol. 6:79–88.
8. Braun, L., et al. 2008. Purification of Toxoplasma dense granule proteins
reveals that they are in complexes throughout the secretory pathway. Mol.
Biochem. Parasitol. 157:13–21.
9. Carruthers, V. B., and L. D. Sibley. 1997. Sequential protein secretion from
three distinct organelles of Toxoplasma gondii accompanies invasion of hu-
man fibroblasts. Eur. J. Cell Biol. 73:114–123.
10. Cesbron-Delauw, M. F., C. Gendrin, L. Travier, P. Ruffiot, and C. Mercier.
2008. Apicomplexa in mammalian cells: trafficking to the parasitophorous
vacuole. Traffic 9:657–664.
11. Chtanova, T., et al. 2008. Dynamics of neutrophil migration in lymph nodes
during infection. Immunity 29:487–496.
12. Contini, C. 2008. Clinical and diagnostic management of toxoplasmosis in
the immunocompromised patient. Parasitologia 50:45–50.
13. Craver, M. P., and L. J. Knoll. 2007. Increased efficiency of homologous
recombination in Toxoplasma gondii dense granule protein 3 demonstrates
that GRA3 is not necessary in cell culture but does contribute to virulence.
Mol. Biochem. Parasitol. 153:149–157.
14. Denkers, E. Y., and B. A. Butcher. 2005. Sabotage and exploitation in mac-
rophages parasitized by intracellular protozoans. Trends Parasitol. 21:35–41.
15. Dixon, S. E., M. M. Bhatti, V. N. Uversky, A. K. Dunker, and W. J. Sullivan,
Jr. 2011. Regions of intrinsic disorder help identify a novel nuclear localiza-
tion signal in Toxoplasma gondii histone acetyltransferase TgGCN5-B. Mol.
Biochem. Parasitol. 175:192–195.
16. Donald, R. G., D. Carter, B. Ullman, and D. S. Roos. 1996. Insertional
tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-
xanthine-guanine phosphoribosyltransferase gene. Use as a selectable
marker for stable transformation. J. Biol. Chem. 271:14010–14019.
17. Donald, R. G., and D. S. Roos. 1995. Insertional mutagenesis and marker
rescue in a protozoan parasite: cloning of the uracil phosphoribosyltrans-
ferase locus from Toxoplasma gondii. Proc. Natl. Acad. Sci. U. S. A. 92:5749–
5753.
18. Donald, R. G., and D. S. Roos. 1993. Stable molecular transformation of
Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate syn-
thase marker based on drug-resistance mutations in malaria. Proc. Natl.
Acad. Sci. U. S. A. 90:11703–11707.
19. Dubey, J. P. 2007. The history and life cycle of Toxoplasma gondii, p. 1–18.
In L. M. Weiss et al. (ed.), Toxoplasma gondii: the model apicomplexan
parasite: perspectives and methods. Elsevier, London, United Kingdom.
20. Fentress, S. J., et al. 2010. Phosphorylation of immunity-related GTPases by
a Toxoplasma gondii-secreted kinase promotes macrophage survival and
virulence. Cell Host Microbe 8:484–495.
21. Ferguson, D. J. 2004. Use of molecular and ultrastructural markers to eval-
uate stage conversion of Toxoplasma gondii in both the intermediate and
definitive host. Int. J. Parasitol. 34:347–360.
22. Fox, B. A., A. A. Belperron, and D. J. Bzik. 1999. Stable transformation of
Toxoplasma gondii based on a pyrimethamine-resistant trifunctional dihy-
drofolate reductase-cytosine deaminase-thymidylate synthase gene that con-
fers sensitivity to 5-fluorocytosine. Mol. Biochem. Parasitol. 98:93–103.
23. Fox, B. A., and D. J. Bzik. 2010. Avirulent uracil auxotrophs based on
disruption of orotidine-5-monophosphate decarboxylase elicit protective
immunity to Toxoplasma gondii. Infect. Immun. 78:3744–3752.
24. Fox, B. A., and D. J. Bzik. 2002. De novo pyrimidine biosynthesis is required
for virulence of Toxoplasma gondii. Nature 415:926–929.
25. Fox, B. A., J. G. Ristuccia, and D. J. Bzik. 2009. Genetic identification of
essential indels and domains in carbamoyl phosphate synthetase II of
Toxoplasma gondii. Int. J. Parasitol. 39:533–539.
26. Fox, B. A., J. G. Ristuccia, J. P. Gigley, and D. J. Bzik. 2009. Efficient gene
replacements in Toxoplasma gondii strains deficient for nonhomologous end
joining. Eukaryot. Cell 8:520–529.
27. Frickel, E. M., et al. 2008. Parasite stage-specific recognition of endogenous
Toxoplasma gondii-derived CD8 T cell epitopes. J. Infect. Dis. 198:1625–
1633.
28. Gendrin, C., A. Bittame, C. Mercier, and M. F. Cesbron-Delauw. 2010.
Post-translational membrane sorting of the Toxoplasma gondii GRA6 pro-
tein into the parasite-containing vacuole is driven by its N-terminal domain.
Int. J. Parasitol. 40:1325–1334.
29. Gigley, J. P., B. A. Fox, and D. J. Bzik. 2009. Cell-mediated immunity to
Toxoplasma gondii develops primarily by local Th1 host immune responses in
the absence of parasite replication. J. Immunol. 182:1069–1078.
30. Gigley, J. P., B. A. Fox, and D. J. Bzik. 2009. Long-term immunity to lethal
acute or chronic type II Toxoplasma gondii infection is effectively induced in
genetically susceptible C57BL/6 mice by immunization with an attenuated
type I vaccine strain. Infect. Immun. 77:5380–5388.
31. Gubbels, M. J., B. Striepen, N. Shastri, M. Turkoz, and E. A. Robey. 2005.
Class I major histocompatibility complex presentation of antigens that es-
cape from the parasitophorous vacuole of Toxoplasma gondii. Infect. Immun.
73:703–711.
32. Holpert, M., U. Gross, and W. Bohne. 2006. Disruption of the bradyzoite-
specific P-type (H)-ATPase PMA1 in Toxoplasma gondii leads to decreased
bradyzoite differentiation after stress stimuli but does not interfere with
mature tissue cyst formation. Mol. Biochem. Parasitol. 146:129–133.
33. Howe, D. K., S. Honore, F. Derouin, and L. D. Sibley. 1997. Determination
of genotypes of Toxoplasma gondii strains isolated from patients with toxo-
plasmosis. J. Clin. Microbiol. 35:1411–1414.
34. Huynh, M. H., and V. B. Carruthers. 2009. Tagging of endogenous genes in
a Toxoplasma gondii strain lacking Ku80. Eukaryot. Cell 8:530–539.
35. Johnson, J. J., et al. 2002. In vitro correlates of Ld-restricted resistance to
toxoplasmic encephalitis and their critical dependence on parasite strain.
J. Immunol. 169:966–973.
36. Jones, J. L., and G. N. Holland. 2010. Annu. burden of ocular toxoplasmosis
in the US. Am. J. Trop. Med. Hyg. 82:464–465.
37. Joyce, B. R., S. F. Queener, R. C. Wek, and W. J. Sullivan, Jr. 2010.
Phosphorylation of eukaryotic initiation factor-2 promotes the extracellular
survival of obligate intracellular parasite Toxoplasma gondii. Proc. Natl.
Acad. Sci. U. S. A. 107:17200–17205.
38. Karasov, A. O., J. C. Boothroyd, and G. Arrizabalaga. 2005. Identification
and disruption of a rhoptry-localized homologue of sodium hydrogen ex-
changers in Toxoplasma gondii. Int. J. Parasitol. 35:285–291.
39. Kim, K., D. Soldati, and J. C. Boothroyd. 1993. Gene replacement in Toxo-
plasma gondii with chloramphenicol acetyltransferase as selectable marker.
Science 262:911–914.
40. Kim, K., and L. M. Weiss. 2008. Toxoplasma: the next 100 years. Microbes
Infect. 10:978–984.
41. Kim, S. K., A. Karasov, and J. C. Boothroyd. 2007. Bradyzoite-specific
surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persis-
tence in the brain and in host control of parasite replication in the intestine.
Infect. Immun. 75:1626–1634.
42. Kirak, O., et al. 2010. Transnuclear mice with predefined T cell receptor
specificities against Toxoplasma gondii obtained via SCNT. Science 328:243–
248.
43. Labruyere, E., M. Lingnau, C. Mercier, and L. D. Sibley. 1999. Differential
membrane targeting of the secretory proteins GRA4 and GRA6 within the
parasitophorous vacuole formed by Toxoplasma gondii. Mol. Biochem. Para-
sitol. 102:311–324.
44. Larson, E. T., et al. 2009. Toxoplasma gondii cathepsin L is the primary target
of the invasion-inhibitory compound morpholinurea-leucyl-homophenyl-
vinyl sulfone phenyl. J. Biol. Chem. 284:26839–26850.
45. McLeod, R., E. Skamene, C. R. Brown, P. B. Eisenhauer, and D. G. Mack.
1989. Genetic regulation of early survival and cyst number after peroral
VOL. 10, 2011 ANALYSIS OF CYST DEVELOPMENT AND LATENT INFECTION 1205
Toxoplasma gondii infection of A
B/B
A recombinant inbred and B10
congenic mice. J. Immunol. 143:3031–3034.
46. Mercier, C., M. F. Cesbron-Delauw, and D. J. P. Ferguson. 2007. Dense
granules of the infectious stages of Toxoplasma gondii: their central role in
the host/parasite relationship, p. 475–492. In D. S. Ajioka et al. (ed.), Tox-
oplasma: molecular and cellular biology. Horizon Bioscience, Norfolk,
United Kingdom.
47. Mercier, C., et al. 2002. Biogenesis of nanotubular network in Toxoplasma
parasitophorous vacuole induced by parasite proteins. Mol. Biol. Cell 13:
2397–2409.
48. Mercier, C., D. K. Howe, D. Mordue, M. Lingnau, and L. D. Sibley. 1998.
Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases acute
virulence in mice. Infect. Immun. 66:4176–4182.
49. Mercier, C., L. Travier, A. Bittame, C. Gendrin, and M. F. Cesbraun-
Delauw. 2010. The dense granule proteins of Toxoplasma gondii, p. 1–31. In
O. De Bruyn and S. Peeters (ed.), Parasitology research trends. Nova Science
Publishers, Hauppage, NY.
50. Montoya, J. G., and J. S. Remington. 2008. Management of Toxoplasma
gondii infection during pregnancy. Clin. Infect. Dis. 47:554–566.
51. Odaert, H., M. Soete, B. Fortier, D. Camus, and J. F. Dubremetz. 1996. Stage
conversion of Toxoplasma gondii in mouse brain during infection and immu-
nodepression. Parasitol. Res. 82:28–31.
52. Robben, P. M., and L. D. Sibley. 2004. Food- and waterborne pathogens: you
are (infected by) what you eat! Microbes Infect. 6:406–413.
53. Roos, D. S. 2005. Genetics: themes and variations in apicomplexan parasite
biology. Science 309:72–73.
54. Rosowski, E. E., et al. 2011. Strain-specific activation of the NF-B pathway
by GRA15, a novel Toxoplasma gondii dense granule protein. J. Exp. Med.
208:195–212.
55. Saeij, J. P., G. Arrizabalaga, and J. C. Boothroyd. 2008. A cluster of four
surface antigen genes specifically expressed in bradyzoites, SAG2CDXY,
plays an important role in Toxoplasma gondii persistence. Infect. Immun.
76:2402–2410.
56. Schaeffer, M., et al. 2009. Dynamic imaging of T cell-parasite interactions in
the brains of mice chronically infected with Toxoplasma gondii. J. Immunol.
182:6379–6393.
57. Schwarz, J. A., A. E. Fouts, C. A. Cummings, D. J. Ferguson, and J. C.
Boothroyd. 2005. A novel rhoptry protein in Toxoplasma gondii bradyzoites
and merozoites. Mol. Biochem. Parasitol. 144:159–166.
58. Sibley, L. D., and J. W. Ajioka. 2008. Population structure of Toxoplasma
gondii: clonal expansion driven by infrequent recombination and selective
sweeps. Annu. Rev. Microbiol. 62:329–351.
59. Sinai, A. P. 2008. Biogenesis of and activities at the Toxoplasma gondii
parasitophorous vacuole membrane. Subcell. Biochem. 47:155–164.
60. Singh, U., J. L. Brewer, and J. C. Boothroyd. 2002. Genetic analysis of
tachyzoite to bradyzoite differentiation mutants in Toxoplasma gondii reveals
a hierarchy of gene induction. Mol. Microbiol. 44:721–733.
61. Soldati, D., and J. C. Boothroyd. 1993. Transient transfection and expression
in the obligate intracellular parasite Toxoplasma gondii. Science 260:349–
352.
62. Su, C., et al. 2003. Recent expansion of Toxoplasma through enhanced oral
transmission. Science 299:414–416.
63. Suzuki, Y., and J. S. Remington. 1988. Dual regulation of resistance against
Toxoplasma gondii infection by Lyt-2 and Lyt-1, L3T4 T cells in mice.
J. Immunol. 140:3943–3946.
64. Torpier, G., et al. 1993. Toxoplasma gondii: differential location of antigens
secreted from encysted bradyzoites. Exp. Parasitol. 77:13–22.
65. Vanchinathan, P., J. L. Brewer, O. S. Harb, J. C. Boothroyd, and U. Singh.
2005. Disruption of a locus encoding a nucleolar zinc finger protein de-
creases tachyzoite-to-bradyzoite differentiation in Toxoplasma gondii. Infect.
Immun. 73:6680–6688.
66. Wallace, G. R., and M. R. Stanford. 2008. Immunity and Toxoplasma
retinochoroiditis. Clin. Exp. Immunol. 153:309–315.
67. Weiss, L. M., and K. Kim. 2000. The development and biology of bradyzoites
of Toxoplasma gondii. Front. Biosci. 5:D391–D405.
68. Wilson, D. C., et al. 2010. Differential regulation of effector- and central-
memory responses to Toxoplasma gondii infection by IL-12 revealed by
tracking of Tgd057-specific CD8 T cells. PLoS Pathog. 6:e1000815.
69. Zhang, Y. W., et al. 1999. Disruption of the Toxoplasma gondii bradyzoite-
specific gene BAG1 decreases in vivo cyst formation. Mol. Microbiol. 31:
691–701.
1206 FOX ET AL. EUKARYOT. CELL
